Bill

Bill > LD538


ME LD538

An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives


summary

Introduced
02/11/2025
In Committee
02/11/2025
Crossed Over
05/20/2025
Passed
05/27/2025
Dead

Introduced Session

Potential new amendment
132nd Legislature

Bill Summary

This bill provides that, at the request of the practitioner prescribing the drug, the prescription drug label for mifepristone, misoprostol and their generic alternatives may include the name of the health care facility that the practitioner is associated with instead of the name of the practitioner.

AI Summary

This bill amends Maine's prescription drug labeling law to provide flexibility for healthcare providers prescribing mifepristone and misoprostol (medications commonly used in medical abortion and pregnancy management) and their generic equivalents. Specifically, the bill allows a prescribing practitioner to request that the prescription drug label display the name of their associated health care facility instead of the individual prescriber's name. This provision appears designed to offer an additional layer of privacy or protection for healthcare providers who prescribe these specific medications, potentially in response to ongoing legal and social tensions surrounding reproductive healthcare. The change would be an optional modification to drug labeling, meaning the prescriber must actively request the facility name replacement, and it applies only to mifepristone, misoprostol, and their generic alternatives.

Committee Categories

Health and Social Services

Sponsors (10)

Last Action

PASSED TO BE ENACTED, in concurrence. (on 05/27/2025)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...